Breaking News, Financial News

Financial Report: Charles River Labs 3Q

Revenues up 5% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Labs 3Q

3Q Revenues: $292.1 million (+5%)

3Q Earnings: $31.2 million (+41%)

YTD Revenues: $876.3 million (+3%)

YTD Earnings: $84.7 million (+7%)

Comments: Research Models and Services (RMS) segment sales were $173.4 million in the quarter, up 4%, driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $118.7 million, up 6%, driven by increased sales to both large biopharma and mid-tier clients.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters